Company news

TELA Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

TELA Bio to Take Part in Connecting the Dots

December 4, 2023

TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference

November 15, 2023

TELA Bio Reports Third Quarter 2023 Financial Results

November 8, 2023

TELA Bio to Announce Third Quarter 2023 Financial Results

October 25, 2023

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

September 17, 2023

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

August 15, 2023

TELA Bio Reports Second Quarter 2023 Financial Results

August 8, 2023

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

July 25, 2023

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

June 14, 2023

TELA Bio to Participate in the Jefferies Global Healthcare Conference

May 24, 2023

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

May 18, 2023

TELA Bio Reports First Quarter 2023 Financial Results

May 10, 2023

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

May 8, 2023

TELA Bio to Participate in the JMP Securities Life Sciences Conference

May 1, 2023

TELA Bio to Announce First Quarter 2023 Financial Results

April 26, 2023

TELA Bio Announces Pricing of Public Offering of Common Stock

April 17, 2023

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

March 28, 2023

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

March 22, 2023

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

March 20, 2023

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

March 15, 2023

TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques

February 20, 2023

TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization

February 13, 2023

TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds

January 8, 2023

TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 20, 2022

TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference

November 20, 2022

TELA Bio Reports Third Quarter 2022 Financial Results

November 8, 2022

TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum

November 2, 2022

TELA Bio to Announce Third Quarter 2022 Financial Results

October 26, 2022

TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair

October 25, 2022

TELA Bio to Participate in Upcoming Investor Conferences

August 31, 2022

TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase

August 22, 2022

TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

August 17, 2022

TELA Bio Announces Proposed Public Offering of Common Stock

August 14, 2022

TELA Bio Reports Second Quarter 2022 Financial Results

August 9, 2022

TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting

August 3, 2022

TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc.

July 19, 2022

TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial

May 30, 2022

TELA Bio Reports First Quarter 2022 Financial Results

May 9, 2022

TELA Bio to Announce First Quarter 2022 Financial Results

April 25, 2022

TELA Bio Appoints D. Taylor Ocasio as General Counsel

April 17, 2022

TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results

March 20, 2022

TELA Bio to Announce Fourth Quarter and Full Year 2021 Financial Results

March 6, 2022

TELA Bio Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

March 2, 2022

TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand

November 9, 2021

TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months

November 8, 2021

TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash

October 31, 2021

TELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer

September 26, 2021

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

September 12, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 29 decks. Every deck is listed under its year.